Medicis’ Solid Q2 OVERSHADOWED by Disappointing Guidance and 4 Stock Analyses to Note

Medicis Pharmaceutical Corp. (NYSE:MRX): According to Deutsche Bank, Medicis’ solid results for Q2 were overshadowed by the company’s disappointing guidance, which it claims represented uneven implementation of the Alternative Fulfillment program. The firm maintains its Buy rating but lowered its price target on the stock.

Investing Insights: Wall Street Brief: Yahoo’s BIG Turnaround Underway, News Corp MISSES.

Anadarko Petroleum Corporation (NYSE:APC): Citigroup thinks that Anadarko’s update regarding its settlement talks with Tronox (TROX) will disappoint the markets. Citi thinks that Anadarko shares currently reflect approximately $3 billion for Tronox, but it believes that the number will probably expand given uncertainty about the judge’s ultimate decision. The firm gives the shares a Buy rating and a $115 price target.

QR Energy LP (NYSE:QRE) sees a Q3 Capex of $10 million to $15 million.

United Rentals, Inc. (NYSE:URI): Following meetings with management, Citigroup believes the recent underperformance in the company’s shares creates an attractive entry point for investors. Citi believes that the rental cycle is still in an upswing, and it maintains a Buy rating and a $46 price target on the stock.

Columbia Laboratories Inc. (NASDAQ:CBRX) price target was increased by Benchmark Co. due to the company’s Q2 earnings surprise, and the firm thinks shares offer an opportunity to capitalize on investor disappointment after the adverse FDA decision previously this year. The firm maintains a Buy rating on the stock.

Don’t Miss: Here’s Why the iPhone Remains KING.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.